(CercleFinance.com) – Sanofi announces the positive results of the clinical trial devoted to Dupixent (dupilumab) in the treatment of moderate to severe, uncontrolled atopic dermatitis of the hands and feet in adults and children. teenager.
Breaking data presented at the American Academy of Dermatology (AAD) Congress show significant improvements in the signs and symptoms of this disease, meeting the study’s primary and secondary endpoints.
‘More than twice as many patients treated with Dupixent showed clear or almost clear skin at 16 weeks, compared to placebo’, underlines the French pharmaceutical giant.
Almost four times as many patients treated with Dupixent experienced a clinically meaningful reduction in itching, with improvements seen from the first week of treatment.